DRIO DarioHealth Corp.

NASDAQ
$1.26

DarioHealth Corp. (DRIO) is expected to report earnings on February 11, 2027, before the market open. The consensus earnings estimate is a loss of $0.61 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -51.4% since its last earnings release on November 12, 2026.

DarioHealth Missed Consensus Estimates
Thursday, November 12, 2026 · 6:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 6:30 AM ET
Earnings Whisper
-
vs ($0.61)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.52

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease.

Sector

Healthcare

Industry

Medical Instruments/Supply

Charts powered in part by Lightweight Charts™ by TradingView.